Monitor ISS and Glass Lewis updated recommendations following this second supplement; a favorable revision could increase passage probability for Proposal 4, removing a small overhang. If the revised plan passes, the dilution impact is lower than originally feared, but the routine nature of this supplement suggests limited near-term price impact.
Price Chart
Executive Summary
Anika Therapeutics filed a second supplement to its proxy statement responding to ISS's unfavorable recommendation on Proposal 4 (equity incentive plan amendment). The board reduced the requested new share increase from 475,000 to 350,000 shares, lowering estimated dilution from ~29.40% to ~24.88%, and is now seeking approval of a 'Revised Seventh Amended Plan' capping total authorized shares at 6,110,000. The matter will be voted on at the June 18, 2026 annual meeting.
Key Facts
- Board cut requested new shares from 475,000 to 350,000 after ISS flagged excessive dilution (estimated 29.40% fully diluted)
- Revised plan would increase total shares reserved from 5,760,000 to 6,110,000, reducing estimated dilution to ~24.88%
- Company noted ~$3.0 million in annualized savings from recent restructuring actions to support disciplined equity usage
- Three-year average burn rate is 3.92% per fiscal years 2023-2025
- Annual meeting scheduled for June 18, 2026; board unanimously recommends voting FOR the revised plan
Financial Impact
Proposed dilution reduced from ~29.4% to ~24.88% by cutting share request by 125,000 shares (26% reduction). No dollar figures for compensation or dilution impact provided.
Risk Factors
- Plan may still fail if ISS recommendation remains unfavorable despite the concession
- Dilution of ~24.88% is still relatively high and could weigh on the stock over time
- Engagement with proxy advisory firms could continue to pressure management on equity usage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-024374 |
| Document: 0001140361-26-024374-index-headers.html | 0001140361-26-024374 |
| Document: 0001140361-26-024374-index.html | 0001140361-26-024374 |
| Document: 0001140361-26-024374.txt | 0001140361-26-024374 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access